Cystic Fibrosis organisations in Australia provide support and services to people with Cystic Fibrosis (CF) and their carers and families. This is complemented by a commitment to research and a quality improvement program focussing on improved clinical care for people with CF.
Every four days a baby is born in Australia with cystic fibrosis (CF) and more than one million Australians are carriers of cystic fibrosis. Cystic Fibrosis Australia (CFA) is committed to improving clinical practice and patient outcomes through its quality improvement programmes and research with the aim of extending life expectancy from 37 to 50 years by 2025.
Cystic Fibrosis is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus.
In addition to working for a cure, Cystic Fibrosis Australia also provides support and advocacy to improve the lives of people with cystic fibrosis. Get involved by raising awareness about CF, participating in a fundraising event or volunteering.
Cystic Fibrosis Australia has established a consistent approach to advocacy across Australia and is now a subject matter expert for government, industry and the media.
The Australian Cystic Fibrosis Research Trust (ACFRT) is managed by Cystic Fibrosis Australia (CFA). Since 1989 it has funded more than 300 projects valued at over $6,000,000.
Visit the media room to browse through number of resources including media representatives, press releases and reports.
Clinical trials are listed below.
Restore CFTR FunctionCompleted with results Location: USA
SNO1: Study of N6022 in people with cystic fibrosis , protocol number Nivalis N30 N6022-1CF1-04
This study tested the safety, tolerability of N6022 and its effects on CFTR biomarkers in people with CF.
Age:
18 Years and Older
Mutation(s):
Two copies F508del
FEV1% Predicted:
40% or greater
Number of Visits:
10
Length of Participation:
6 weeks
Nutritional-GICompleted with results Location: USA
Study of in-line digestive enzyme cartridge (Relizorb) in people with CF who are currently receiving enterel tube feedings , protocol number Alcresta 0000497
This study took place at multiple care centres across the US. It looked at the safety and effectiveness of Relizorb, a new tube feeding in-line digestive enzyme cartridge. This cartridge is used with tube feedings to deliver digestive enzymes.
4 Years to 82 Years
No Mutation Requirement
Less than 100%
4
27 days
Anti-InfectiveCompleted with results Location: USA
Arikace for Nontuberculous Mycobacteria (NTM) , protocol number Insmed 112
The purpose of this study was to determine whether Arikace is effective in treating recalcitrant nontuberculous mycobacterial lung disease. The safety and tolerability of Arikace in this patient population was also assessed.
12 Years to 75 Years
No FEV1 Limit
0
12 weeks
SNO4: Study of N91115 in people with cystic fibrosis ages 18 and older with two copies of F508del-CFTR mutation. , protocol number Nivalis N91115-2CF-03
This study is taking place at multiple care centers across the U.S. It will look at the safety of the drug N91115 as well as how the body processes the drug, in people with CF.
8
Restore CFTR FunctionClosed to enrollment Location: USA
Phase 2 study of riociguat in adults with CF , protocol number Bayer 63-2521/17020
This study is taking place at multiple care centers across the U.S. It will look at the safety, tolerability and effectiveness of the oral drug riociguat and will use a placebo control.
60 to 90%
9
28 days
ASSURE: Study of Relizorb in people with CF who receive enteral tube feeding , protocol number Alcresta 0000498
This open label study is taking place at multiple care centres across the US. It will look at the safety, tolerability and effectiveness of Relizorb, a new digestive enzyme cartridge for people using enteral tube feedings.
4 Years and Older
5
4 months
SOLUTION: Study of Liprotamase in people with CF , protocol number NCT00449878 AN-EP13331 - Anthera
This study is taking place at multiple care centres across the US. It will look at the safety and effectiveness of the drug Liprotamase in people with CF who are currently taking digestive enzymes.
7 Years and Older
30% or greater
28 weeks
Nutritional-GIEnrolling Location: USA
SIMPLICITY: Phase 3 study of liprotamase in people with CF-related pancreatic insufficiency , protocol number Anthera AN-EP13332
This two-part study is taking place at multiple care centres across the US. It will look at the safety and effectiveness of a new, water-soluble formulation of liprotamase.
28 Days to 17 Years
7
24 weeks
Anti-InflammatoryCompleted with results Location: USA
AquADEKs-2: Effects of an antioxidant-enriched multivitamin on inflammation and oxidative stress in people with CF , protocol number AquADECKs-IP-12
This study took place at multiple care centres across the US. It looked at the effects on an anti-oxidant enriched multivitamin supplement on inflammation and oxidative stress in people with CF.
10 Years and Older
40 to 100%
20 weeks
ObservationalCompleted with results Location: USA
BONUS: Baby Observational and Nutritional Study , protocol number BONUS-IP-11, BONUS10K0
This study took place at multiple care centres across the US. It aimed to gain a better understanding of the factors that interfere with good growth in infants with CF.
Less than 15 weeks
12 months